To test this hypothesis, the key protein of the system Xc− was detected in tumor tissues after treatment, and the results showed that Efm combined with sorafenib decreased the SLC7A11 protein expression (Figure 6a) in tumors compared to that with E. Coli combined with sorafenib and sorafenib alone. Here, SLC7A11 is linked to neoplasm.